Brief: Clover’s Vaccine Candidate Reduced Household Transmission Of Sars-Cov-2
30/11/2022 12:09
Nov 30 (Reuters) - Clover Biopharmaceuticals Ltd
2197.HK :
* CLOVER’S VACCINE CANDIDATE REDUCED HOUSEHOLD TRANSMISSION
OF
SARS-COV-2 IN STUDY PUBLISHED IN CLINICAL INFECTIOUS DISEASES
Source text for Eikon: ID:nGNXch1P2V
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune